Our Sponsors
We would like to thank each of our sponsors for their generous support - as without them this event would not be possible.
For more information on the sponsorship opportunities available, contact Tara Lovegrove at tara.lovegrove@pharmatimes.com
- support healthcare innovation and technology that will benefit patients now and in the future
- drive faster translation of basic science discoveries into tangible benefits for patients and the economy
- help develop the people who conduct and contribute to applied health research.

About the ABPI
We represent innovative biopharmaceutical companies in the UK.
Our industry, a major contributor to the economy, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing new medicines, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI also negotiates for the branded pharmaceutical industry in statutory consultations, including the pricing scheme for medicines in the UK.
The NIHR is funded by the UK government to improve the health and wealth of the nation through research and represents the most integrated health research system in the world. We partner with all funders of research, including industry, to:
More about us: https://www.nihr.ac.uk/partners-and-industry/industry/

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about and Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

PPD is delighted to sponsor PharmaTimes International Clinical Researcher of the Year 2021.
PPD is a leading global contract research organisation providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organisations. With locations in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.

Premier Research, a clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.
As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.
Whether it's developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.
Visit premier-research.com.
Media Contact:
Karen Brown, Vice President
Karen.Brown@premier-research.com

PRA Health Sciences is now an ICON plc company. ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON operates from 150 locations in 47 countries and has approximately 38,000 employees.

ICT (International Clinical Trials) magazine provides in-depth comment and analysis on the developments in clinical research for decision makers operating in the field.
Each quarterly issue features articles written by key opinion leaders, and presents dedicated sector events, insightful profiles, interviews, and reviews, offering an in-depth guide to the industry.

Bionical Emas is a global Contract Research Organisation combining Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to pioneer the way life-changing medicines are developed and accessed for patients around the world.
Our range of services enables us to maximise access, collect data and generate evidence at every point along the drug development pathway. This means we can simultaneously address the immediate and future needs of patients.
Our unique business model, with its range of complimentary services and capabilities, provides an entry point to become the preferred partner to many of the world’s leading pharma and biotech companies.